{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+Renal+Cell+Carcinoma&page=5", "query": { "condition": "Advanced or Metastatic Renal Cell Carcinoma", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 224, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+Renal+Cell+Carcinoma&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+Renal+Cell+Carcinoma&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T09:27:02.350Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04370509", "title": "Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Clear Cell Renal Cell Carcinoma", "Recurrent Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Axitinib (VEGF-TKI)", "type": "DRUG" }, { "name": "Cytoreductive Nephrectomy (CN)", "type": "PROCEDURE" }, { "name": "Metastasectomy (MET)", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-02-09", "completion_date": "2025-02-28", "has_results": true, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-10-11T09:27:02.350Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04370509" }, { "nct_id": "NCT03219333", "title": "A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Transitional Cell", "Urinary Bladder Neoplasms", "Urologic Neoplasms", "Renal Pelvis Neoplasms", "Urothelial Cancer", "Ureteral Neoplasms", "Urethral Neoplasms" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2017-10-08", "completion_date": "2023-07-28", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-10-11T09:27:02.350Z", "location_count": 54, "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Phoenix, Arizona + 45 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03219333" }, { "nct_id": "NCT03692338", "title": "INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2018-11-19", "completion_date": "2019-12-09", "has_results": false, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-10-11T09:27:02.350Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03692338" }, { "nct_id": "NCT00003105", "title": "Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer", "Transitional Cell Cancer of the Renal Pelvis and Ureter" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "1997-09", "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2013-07-03", "last_synced_at": "2026-10-11T09:27:02.350Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003105" }, { "nct_id": "NCT07383441", "title": "Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Clostridium butyricum CBM 588 Probiotic Strain", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab and Recombinant Human Hyaluronidase", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 718, "start_date": "2026-06-05", "completion_date": "2034-01-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-11T09:27:02.350Z", "location_count": 41, "location_summary": "Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07383441" }, { "nct_id": "NCT04006522", "title": "89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "89Zr-DFO-Atezolizumab", "type": "DRUG" }, { "name": "Positron Emission Tomography/Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "James Brugarolas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2019-10-02", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-11T09:27:02.350Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04006522" }, { "nct_id": "NCT00407485", "title": "VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Bladder", "Distal Urethral Cancer", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Proximal Urethral Cancer", "Recurrent Bladder Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Squamous Cell Carcinoma of the Bladder", "Stage III Bladder Cancer", "Stage III Urethral Cancer", "Stage IV Bladder Cancer", "Transitional Cell Carcinoma of the Bladder", "Urethral Cancer Associated With Invasive Bladder Cancer" ], "interventions": [ { "name": "ziv-aflibercept", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2006-11", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2014-10-20", "last_synced_at": "2026-10-11T09:27:02.350Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00407485" }, { "nct_id": "NCT05479812", "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "WTX-124", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Werewolf Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2022-08-15", "completion_date": "2026-04-22", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-11T09:27:02.350Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05479812" }, { "nct_id": "NCT05411081", "title": "Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Papillary Renal Cell Carcinoma", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2023-03-24", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-11T09:27:02.350Z", "location_count": 198, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 157 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05411081" }, { "nct_id": "NCT05597839", "title": "Study of DF9001 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "DF9001", "type": "DRUG" }, { "name": "KEYTRUDA® (pembrolizumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-11-15", "completion_date": "2025-08-15", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-11T09:27:02.350Z", "location_count": 17, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05597839" } ] }